The specter of generic rivalry has long loomed around copyright’s iconic drug, Sildenafil, raising questions about the outlook of related medicinal investments. While first times saw significant profits, the patent https://pharma224901.acidblog.net/73185583/the-copyright-and-big-pharma-a-risky-opportunity